Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Future concepts in bronchodilation for COPD: dual- <i>versus</i> monotherapy.

European respiratory review : an official journal of the European Respiratory Society·2021

Same author

Comparative Impact of Depressive Symptoms and FEV<sub>1</sub>% on Chronic Obstructive Pulmonary Disease.

Annals of the American Thoracic Society·2021

Same author

A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial.

The European respiratory journal·2021

Same author

Barriers to antigen detection and avoidance in chronic hypersensitivity pneumonitis in the United States.

Respiratory research·2021

Same author

Identifying organ dysfunction trajectory-based subphenotypes in critically ill patients with COVID-19.

Scientific reports·2021

Same author

Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial.

ERJ open research·2021

Search research articles

Related Experiment Video

Updated: Mar 20, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Pharmacogenetics and interstitial lung disease.

Justin M Oldham¹, Imre Noth, Fernando J Martinez

¹aDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, The University of California at Davis, Sacramento, California bDepartment of Medicine, Section of Pulmonary and Critical Care Medicine, The University of Chicago, Chicago, Illinois cDepartment of Internal Medicine, Weill Cornell Medical School, New York City, New York, USA.

Current Opinion in Pulmonary Medicine

|June 3, 2016

Summary

Pharmacogenetics explores genetic factors influencing drug response in interstitial lung diseases (ILD). A TOLLIP gene variant impacts N-acetylcysteine therapy response in idiopathic pulmonary fibrosis (IPF) patients.

More Related Videos

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

Related Experiment Videos

Last Updated: Mar 20, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

Area of Science:

Pharmacogenetics
Genomics
Pulmonary Medicine

Background:

Interstitial lung disease (ILD) encompasses diverse disorders with variable prognoses.
Pharmacogenetics investigates genetic influences on drug metabolism and disease activity.
Genetic polymorphisms are increasingly linked to ILD susceptibility and immune signaling.

Purpose of the Study:

Review drug-specific and disease-specific polymorphisms affecting therapeutic response in ILD.
Highlight a novel drug-gene interaction in idiopathic pulmonary fibrosis (IPF).
Discuss the potential of pharmacogenetics in advancing ILD understanding and personalized medicine.

Main Methods:

Review of existing literature on pharmacogenetics in ILD.
Analysis of gene polymorphisms associated with ILD susceptibility.
Examination of a specific drug-gene interaction in an IPF clinical trial.

Main Results:

High-throughput genomics identifies gene variants linked to IPF and connective tissue disease-related ILDs.
A variant in the TOLLIP gene is associated with differential response to N-acetylcysteine in IPF patients.
Limited pharmacogenetic studies exist for ILD, indicating a need for further research.

Conclusions:

Pharmacogenetic investigations in ILD are currently limited but hold significant potential.
Identifying specific genetic variants can improve understanding of disease mechanisms.
Pharmacogenetics promises to facilitate personalized medicine approaches for ILD patients.